MRI lesions

Delayed Ocrevus Infusion May Increase MRI-based RRMS Risk

An extended interval between maintenance doses of OcrevusĀ (ocrelizumab) may increase the risk of MRI-based disease activity in people with relapsing-remitting multiple sclerosisĀ (RRMS), according to a real-world, multicenter study in Italy. In fact, an extended interval dosing (by one month or longer) was associated with a fivefold higher risk…

Ozanimod Reduces Multiple Sclerosis Relapse Rate, Phase 3 Trial Shows

A Phase 3 clinical trial evaluating the safety and effectiveness of ozanimod (RPC-1063) in patients withĀ relapsing multiple sclerosis (RMS)Ā shows treatment reduced the disease’s annualized relapse rate (ARR), researchers reported. The Phase 3 SUNBEAM trial (NCT02294058)Ā testedĀ ozanimod, anĀ oral, selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator designed to…